Immune Responses to Vaccines in Patients with Hematologic Diseases
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".
Deadline for manuscript submissions: 31 January 2025 | Viewed by 171
Special Issue Editor
Interests: chronic myeloproliferative neoplasms; acute myeloid leukemia; anti-cancer vaccines; immune responses to COVID-19 vaccines in patients with hematologic diseases; evidence-based medicine; clinical practice guidelines; pharmacoeconomic analysis; decision analysis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Patients with rare blood cancers (blood neoplasms) faced challenges during the COVID-19 pandemic until active and passive measures were implemented. The severity of the disease is influenced by various factors, such as the patient’s immunity and treatment. The safety and efficacy of disease measures may vary depending on the SARS-CoV-2 variant and the disease epidemiology. To address these issues, this Special Issue will gather an important collection of articles that explore the latest research and development efforts in this field. We welcome original articles, reviews, and viewpoints covering vaccines and the experiences of hematologists and infectious disease specialists who have treated blood neoplasm patients with SARS-CoV-2.
Prof. Dr. Monia Marchetti
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- SARS-CoV-2
- COVID-19
- leukemia
- lymphoma
- multiple myeloma
- chronic myeloproliferative neoplasms
- immune thrombocytopenia
- tixagevimab/cilgavimab
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
